miR-223-5p Suppresses Tumor Growth and Metastasis in Non-Small Cell Lung Cancer by Targeting E2F8.


Journal

Oncology research
ISSN: 1555-3906
Titre abrégé: Oncol Res
Pays: United States
ID NLM: 9208097

Informations de publication

Date de publication:
05 Feb 2019
Historique:
pubmed: 5 4 2018
medline: 21 3 2019
entrez: 5 4 2018
Statut: ppublish

Résumé

miR-223-5p has been demonstrated to regulate the development and progression of various cancers, such as hepatocellular carcinoma, breast cancer, and gastric carcinoma. However, the role of miR-223-5p in non-small cell lung cancer (NSCLC) requires further investigation. In this study, we found that the expression of miR-223-5p was significantly downregulated in NSCLC tissues and cell lines. Moreover, the expression level of miR-223-5p is negatively correlated with the malignance of NSCLC. We found that overexpression of miR-223-5p remarkably suppressed the proliferation of NSCLC cells in vitro and in vivo. miR-223-5p overexpression also led to reduced migration and invasion in NSCLC cells. Mechanistically, we found that E2F8, a key transcription factor involved in many kinds of biological processes, was a direct target gene of miR-223-5p. Overexpression of miR-223-5p significantly decreased the mRNA and protein levels of E2F8 in NSCLC cells. We also showed that restoration of E2F8 rescued the proliferation, migration, and invasion of miR-223-5p-overexpressing NSCLC cells. Taken together, our findings demonstrated that miR-223-5p suppressed NSCLC progression through targeting E2F8.

Identifiants

pubmed: 29615147
doi: 10.3727/096504018X15219188894056
pmc: PMC7848460
doi:

Substances chimiques

E2F8 protein, human 0
MIRN223 microRNA, human 0
MicroRNAs 0
Repressor Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

261-268

Références

Oncotarget. 2016 Apr 26;7(17):23757-71
pubmed: 26992224
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
pubmed: 19474385
Int J Cancer. 2010 Mar 15;126(6):1283-90
pubmed: 19877123
Cancer Genomics Proteomics. 2018 Jan-Feb;15(1):1-15
pubmed: 29275359
J Exp Clin Cancer Res. 2010 Nov 22;29:151
pubmed: 21092188
J Biol Chem. 2010 Dec 10;285(50):39551-63
pubmed: 20923760
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
pubmed: 20610543
Cancer Med. 2016 Oct;5(10):2899-2908
pubmed: 27683099
Gastroenterology. 2008 Jul;135(1):257-69
pubmed: 18555017
Oncotarget. 2015 Jan 30;6(3):1740-9
pubmed: 25638153
Mol Cancer Res. 2011 Jul;9(7):824-33
pubmed: 21628394
Sci Rep. 2014 Dec 18;4:7546
pubmed: 25519054
Future Med Chem. 2013 Jun;5(9):983-5
pubmed: 23734680
Med Oncol. 2014 Nov;31(11):256
pubmed: 25270282
Neurosci Lett. 2010 May 26;476(1):18-22
pubmed: 20347935
J Natl Cancer Inst. 2015 Jun 18;107(9):
pubmed: 26089541
Cancer Sci. 2016 Jan;107(1):84-94
pubmed: 26509963
Genes Dev. 2006 Mar 1;20(5):515-24
pubmed: 16510870
Cancer Res. 2010 Jan 15;70(2):782-91
pubmed: 20068156
Med Oncol. 2014 Dec;31(12):298
pubmed: 25367852
Cancer Biol Ther. 2006 Jul;5(7):777-8
pubmed: 16880736
BMC Cancer. 2015 Jun 09;15:461
pubmed: 26055874
PLoS One. 2014 Jan 06;9(1):e84859
pubmed: 24400121
J Thorac Cardiovasc Surg. 2005 Jul;130(1):136-40
pubmed: 15999053
J Mol Diagn. 2013 Sep;15(5):695-705
pubmed: 23945108
J Exp Clin Cancer Res. 2017 Mar 7;36(1):40
pubmed: 28270228
Biomed Pharmacother. 2013 Jun;67(5):381-6
pubmed: 23601845
Blood. 2009 May 21;113(21):5237-45
pubmed: 19144983
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Lancet Oncol. 2007 Sep;8(9):784-96
pubmed: 17714993
J Biomed Sci. 2011 Mar 31;18:24
pubmed: 21453483
Br J Cancer. 2012 May 22;106(11):1826-32
pubmed: 22549179
J Integr Neurosci. 2016 Jun;15(2):205-21
pubmed: 27345028

Auteurs

Liyan Dou (L)

Department of Cardiology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, P.R. China.

Kaiyu Han (K)

Department of Respiratory Medicine, the Second Affiliated Hospital of Harbin Medical University, Harbin, P.R. China.

Mochao Xiao (M)

Department of Cardiology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, P.R. China.

Fuzhen Lv (F)

Department of Respiratory Medicine, the Second Affiliated Hospital of Harbin Medical University, Harbin, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH